Clinical Study Notes: Unipolar and Bipolar Mood Disorders

Part 1: Unipolar Mood Disorders
1. Systemic Biological Impact & Screening
  • Multi-Factorial Etiology: Unipolar depression is a biopsychosociocultural condition affecting mind, body, and spirit.

  • Pro-Inflammatory State: Both depression and anxiety are pro-inflammatory states. Anxiety additionally increases sympathetic nervous system (SNS) activity.

  • Cardiovascular & Medical Comorbidities:

    • Depression significantly increases risks of cardiovascular disease (CVD), myocardial infarction (MI), stroke (CVA), and diabetes progression.

    • Post-MI depression increases 1st1\text{st}-year mortality risk 4×4\times and elevates post-heart attack stroke risk by 50%50\%.

  • Diagnostic & Screening Assessment:

    • Biomarkers: No universal diagnostic blood tests or biomarkers currently exist; diagnosis relies on clinical assessment, Mental Status Examination (MSE), and ruling out physiological mimics (e.g., hypothyroidism via TSH, chronic fatigue syndrome, CBC with differential).

    • Measurement-Based Care (MBC): Utilizes self-report Measurement-Based Questionnaires (MBQs) such as the PHQ-9 (new standard for MDD), Beck Depression Inventory (BDI), Zung Self-Rating Depression Scale (ZDRS), and Geriatric Depression Scale (GDS).

    • Universal screening is recommended for ages 12−18 years12 - 18\text{ years} and all depressed individuals must be screened for suicide risk.

2. Clinical Subtypes & Diagnostic Criteria
  • Major Depressive Disorder (MDD):

    • Threshold: Requires ≥5\ge 5 symptoms present for most of the day, nearly every day, for at least 2 weeks2\text{ weeks}.

    • Core Criteria: Must include either Depressed Mood (Dysphoria) or Anhedonia (loss of interest or pleasure).

    • Additional Symptoms: Appetite or weight changes (∼5%\sim 5\% body weight change), sleep disturbances, low energy/fatigue, psychomotor agitation (PMA) or retardation (PMR), poor concentration/decision-making, worthlessness or inappropriate guilt, and suicidal ideation (SI).

  • Dysthymia (Persistent Depressive Disorder):

    • Chronic mild-to-moderate depression present ≥50−60%\ge 50 - 60\% of the time for ≥2 years\ge 2\text{ years} without remission.

    • Requires ≥2\ge 2 symptoms (appetite changes, sleep issues, fatigue, low self-esteem, poor concentration, hopelessness) without a Major Depressive Episode in the first 2 years2\text{ years}.

  • Disruptive Mood Dysregulation Disorder (DMDD):

    • Pediatric diagnosis (ages 6−18 years6 - 18\text{ years}, onset before age 10 years10\text{ years}) featuring severe, recurrent temper outbursts (≥3 times/week\ge 3\text{ times/week} for ≥12 months\ge 12\text{ months}) with persistent anger and irritability between outbursts.

  • Other Depressive Subtypes:

    • Postpartum Depression: Frequently presents with severe anxiety regarding infant well-being.

    • Seasonal Affective Disorder (SAD): Linked to seasonal light reduction; managed with phototherapy and Omega-3 fatty acids (pure EPA).

    • Adjustment Disorder with Depressed Mood: Short-term depressive response to an identifiable life stressor.

    • Premenstrual Dysphoric Disorder (PMDD), Psychotic Depression, Substance-Induced Mood Disorder.

3. Epidemiology & High-Risk Populations
  • Gender Differences: Women experience MDD at a 2:12:1 ratio compared to men (25−30%25 - 30\% lifetime prevalence). Men have a 3×3\times higher completed suicide rate, primarily utilizing firearms.

  • Pediatric & Adolescent Populations:

    • 14%14\% experience a Major Depressive Episode before age 15 years15\text{ years}. Suicide is a leading cause of death in ages 10−24 years10 - 24\text{ years}. Past history of self-harm is the single strongest predictor of suicide worldwide.

  • Older Adults:

    • Highest completed suicide rate occurs among Caucasian males age >75 years> 75\text{ years}.

    • Late-life depression can manifest as "Pseudo-Dementia" (cognitive deficits secondary to depression) and is an independent risk factor for dementia.

  • High-Stress & Vulnerable Groups: Populations experiencing chronic social or minority stress experience heightened psychiatric burden and health disparities.

4. Interventions & Pharmacological Management
  • Levels of Prevention:

    • Primary: Focuses on community resilience, parental support, wellness, exercise, and health education.

    • Secondary: Screen and intervene using MBQ tools (e.g., PHQ-9), early psychotherapy (CBT, IPT), and medication initiation.

    • Tertiary: Advanced therapies for chronic cases, including Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), and Deep Brain Stimulation (DBS).

  • Antidepressant Considerations:

    • Suicide Risk Window: During weeks 1−21 - 2 of antidepressant initiation, increased physical energy and motivation precede mood elevation, creating a window of heightened risk to execute a suicide plan.

    • End-of-Life / Palliative Care: Psychostimulants (e.g., Methylphenidate) are the treatment of choice due to rapid onset of action when time constraints preclude traditional antidepressants.

    • MAOIs: Require strict dietary avoidance of tyramine-rich foods (aged cheeses, organ meats, fermented foods, wine/beer) to prevent life-threatening hypertensive crisis.


Part 2: Bipolar Spectrum Disorders
1. Categorization & Episode Characteristics
  • Bipolar Spectrum Classifications:

    • Bipolar I Disorder (BAD-I): Characterized by ≥1\ge 1 Manic Episode or Mixed Episode (1 week1\text{ week} of simultaneous mania and MDD). Major Depressive Episodes frequently occur but are not strictly required.

    • Bipolar II Disorder (BAD-II): Characterized by ≥1\ge 1 Hypomanic Episode ++ ≥1\ge 1 Major Depressive Episode. Full manic episodes never occur.

    • Cyclothymic Disorder: Chronic mood instability lasting ≥2 years\ge 2\text{ years} with alternating hypomanic and dysthymic symptoms without full MDE or Mania.

    • Rapid Cycling Specifier: Defined as ≥4\ge 4 mood episodes (mania or hypomania) within a single year.

  • Clinical Phases:

    • Manic Episode: Abnormally elevated, expansive, or euphoric mood for ≥1 week\ge 1\text{ week} with ≥3\ge 3 symptoms (or irritable mood with ≥4\ge 4 symptoms): grandiosity, decreased need for sleep (<4 hours< 4\text{ hours}), pressured speech, flight of ideas, distractibility, increased goal-directed activity, and reckless impulsivity.

    • Hypomanic Episode: Elevated or irritable mood lasting at least 4 consecutive days4\text{ consecutive days} with ≥3\ge 3 manic symptoms. Causes observable functional changes but does not require hospitalization or produce psychotic features.

2. Nursing Management of Acute Mania
  • Safety & Physiological Needs (Highest Priority):

    • Provide high-calorie finger foods, frequent water/hydration, structured rest periods, and a low-stimulation environment.

  • Behavioral Control & Communication:

    • Use calm, firm, assertive directives for limit-setting regarding impulsive or inappropriate behaviors.

    • If limit-setting is ineffective, redirect energy into healthy, structured physical outlets.

    • Do not argue with or validate grandiose delusions; connect to underlying emotions.

3. Mood Stabilizers & Laboratory Monitoring
  • Lithium Carbonate (Lithobid):

    • Therapeutic Window: 0.6−1.2 mmol/L0.6 - 1.2\,\text{mmol/L}. Renal metabolism (monitor BUN and Serum Creatinine).

    • Mechanism & Fluid Dynamics: Replaces sodium (Na+\text{Na}^+) ions and inhibits ADH, leading to diuresis and thirst.

    • Patient Teaching: Drink 8−10 glasses8 - 10\text{ glasses} of water daily. Maintain consistent dietary sodium and caffeine intake (sudden sodium drops cause lithium level spikes; increased caffeine lowers levels). Take with meals to reduce GI upset.

    • Toxicity Signs: Nausea, vomiting, severe diarrhea, coarse hand tremor, ataxic gait, nystagmus, dysarthria, renal impairment, seizures, coma.

  • Anticonvulsant Mood Stabilizers:

    • Valproic Acid (Depakote): Teratogenic (black box warning for neural tube defects); requires LFT monitoring (AST, ALT).

    • Carbamazepine (Tegretol) & Lamotrigine (Lamictal): High risk for Stevens-Johnson Syndrome (SJS), a toxic skin emergency marked by fever, blistering rash, and mucous membrane lesions. Hold medication and report immediately.

    • Phenytoin (Dilantin): Therapeutic range 10−20 μg/mL10 - 20\,\mu\text{g/mL}. Side effects include gingival hyperplasia requiring routine dental hygiene.

4. Suicide Assessment & Crisis De-escalation
  • ASQ Screening Tool Routine:

    • Direct assessment questions (e.g., current suicidal intent).

    • Answering "Yes" to acute intent requires immediate action: stay with the patient, remove lethal objects, notify provider, and initiate an urgent mental health evaluation STAT.

  • De-escalation Strategies:

    • Maintain a calm, non-reactive presence; build rapport using active, reflective listening.

    • Use collaborative problem-solving and establish a concrete safety plan for continuity of care.

    • Apply legal and ethical principles including duty to protect, least restrictive measures, and thorough documentation.